- Home
- ENLV
as 11-14-2024 12:33pm EST
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
| Founded: | 2005 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 31.5M | IPO Year: | 1995 |
| Target Price: | $9.50 | AVG Volume (30 days): | 173.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $4.59 | Next Earning Date: | 11-30-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Enlivex Therapeutics Ltd. News
ENLV Breaking Stock News: Dive into ENLV Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 hours ago
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
GlobeNewswire
2 days ago
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Zacks
14 days ago
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
MT Newswires
15 days ago
Enlivex Therapeutics Gets Japan Patent Notice for Allocetra in Osteoarthritis Treatment
GlobeNewswire
15 days ago
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
GlobeNewswire
2 months ago
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
GlobeNewswire
2 months ago
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Zacks
2 months ago
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
Compare ENLV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENLV Enlivex Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.